1. You mention in situ bioremediation hasn’t been tested for pharmaceuticals,,, so isn’t the whole “bioremediation is promising” argument kinda premature?
You clearly state that in situ methods like bioventing and bioslurping have not been reported for pharma waste. That feels like a huge gap. If we don’t know if these work outside the lab, can we really call bioremediation a viable alternative yet? It feels like we’re still very much in the bench-scale phase.
2. Where’s the data on toxicity after degradation? Just saying less toxic doesn’t really cut it.
You mention microbes break drugs into “non-toxic” or “more biodegradable” forms; but there’s no data shown. For stuff like chloramphenicol or diclofenac, sometimes breakdown products can be more toxic. Without that analysis, aren’t we sort of assuming the problem is solved without proof?